These are not the same kind of treatment, and only one of them holds an FDA approval for the under-eye. Hyaluronic acid filler is a manufactured gel that physically fills the hollow. Platelet-rich fibrin, or PRF, is made from a tube of your own blood. It is spun in a centrifuge and injected to improve skin quality.
Four hyaluronic acid fillers carry a US FDA approval specifically for the infraorbital hollow: Juvederm Volbella XC (approved 28 May 2021), Restylane Eyelight (8 May 2023), Belotero Balance (+) Lidocaine (27 September 2023) and RHA Redensity Eye and Eye Lido (12 May 2026). Each reached that point through a randomised, controlled, multicentre trial with about a year of follow-up. PRF has no FDA approval for any facial cosmetic use.
PRF's evidence is thinner, and it measures something different. A 2025 systematic review of 14 periorbital studies found PRF associated with improvements in skin texture, wrinkles and crepiness. The same review noted no standardised centrifugation protocols and inconsistent measurement. It also noted improvements that "often diminished by 6 months." A 2026 review of 26 studies concluded there was "notable variability in preparation methods limiting clear conclusions," with mixed objective results for wrinkles and texture.
No trial has compared PRF against hyaluronic acid filler under the eyes. This is a comparison of two evidence bases at very different stages of maturity. It is not a contest anyone has run. The biggest practical difference between them is that filler can be dissolved.
No manufactured material is left behind. What goes in is a concentrate of your own platelets and fibrin.
A manufactured Class III medical device approved for a specific, named area.
The centrifuges and kits used to prepare them are cleared through the 510(k) route for preparing platelet concentrates. Clearance of a preparation device is not approval of a treatment, so injecting it into the face proceeds as off-label practice.
Juvederm Volbella XC, for "the improvement of infraorbital hollowing in adults over the age of 21"; Restylane Eyelight; Belotero Balance (+), for "volume augmentation for the improvement of the infraorbital hollow in adults over the age of 21"; and RHA Redensity Eye and Eye Lido, for the infraorbital region in adults aged 22 or older.
It is not a volume treatment, which is the real mismatch when the complaint is a hollow.
The gel occupies the space under the eye from the day it goes in.
The 2025 review of 14 periorbital studies included 5 on PRF, 10 on PRP and 1 comparing the two, with samples from single cases up to 68 people. Its authors declared no conflicts of interest.
Volbella XC's infraorbital trial randomised 140 people, 105 treated and 35 untreated controls: 83.1% were responders at month 3 against 15.6% of controls, and 73.4% at month 12. Belotero Balance (+) reported 80.6% at week 8 and 81.4% at week 48 on its own scale.
Studies of platelet-rich plasma in this area followed people for an average of three months, with a range of one to six.
In a retrospective study of 155 patients treated with a mean of 0.45 mL per side, improvement was still present at 18 months. Small MRI series have found hyaluronic acid still detectable years after injection, which is a signal on a scan rather than a visible result.
Hyaluronidase has no target in a blood-derived product.
This is the clearest practical advantage of hyaluronic acid under the eyes, and the same enzyme is the emergency treatment if filler blocks an artery.
Being autologous is not the same as being risk free.
Gel placed too superficially scatters blue light through skin that is the thinnest on the body, which is called the Tyndall effect. Hyaluronic acid also draws water, and this area drains poorly, so swelling over the cheekbone can persist for months. Neither has a reliable published incidence figure.
Platelet-rich plasma appears in the published blindness case series, inside a 3.4% "other" group alongside poly-L-lactic acid. "It is only your own blood" is not a safety argument.
Hyaluronic acid was the product in 79.6% of 365 filler blindness cases published between 2018 and 2023, which mostly reflects how much of it is injected. Unlike the alternatives, it can at least be dissolved.
Three things make this area its own problem. The skin is the thinnest on the body. Anything placed too superficially shows through. That is where blue-grey Tyndall discoloration comes from. Drainage here is poor, hemmed in by a tight orbital retaining ligament and the muscle around the eye. So hyaluronic acid pulling water in can leave puffiness over the cheekbone that lasts months rather than days. And the arteries here connect to the circulation that supplies the eye. That is why vision change after an injection in this region is an emergency and not a side effect to watch.
A 2025 review of periorbital hyaluronic acid complications sorts them into groups worth knowing by name. Immediate reactions include redness, early swelling and bruising. Early problems include vision loss, infection, contour irregularity and persistent swelling. Then come late swelling and late contour irregularity, blue discoloration, and filler that ends up inside the orbit. Immediate reactions were the most commonly reported. Early contour irregularities and blue discoloration came next.
This is the single most important caveat on the PRF side. There is no standardised preparation. Spin speed, spin time, tube type and what fraction gets injected all vary between clinics and between studies. Reviewers have repeatedly named that variability as the reason clear conclusions cannot be drawn. Commentators in the plastic surgery literature have gone further. They note that the vast majority of authors do not even report the final platelet concentration they injected.
One widely cited description of "PRF gel" for the eye area combines denatured albumin with liquid PRF to make an injectable gel. It is a technique article describing an approach, not a trial. Its senior author is medical director of a company that manufactures and distributes PRF gel kits. That does not make the technique wrong. It does mean it is expert opinion with a commercial interest attached. It should not be read as comparative evidence.
No randomised head-to-head of PRF against hyaluronic acid filler for the tear trough has been published: So the comparison that can be made honestly is about the maturity of the two evidence bases. It is not about which works better.
On one side are randomised, evaluator-blinded, controlled, multicentre trials with twelve months of follow-up. They were reviewed by the FDA and tied to a named indication for this exact anatomy. They were also manufacturer-sponsored, and they used manufacturer-developed rating scales. On the other side are case series, small cohorts and technique papers. They have no standard protocol and no approval for this use, and their benefits often fade by six months. Different maturity is not the same as different effectiveness. Nobody has measured the second thing.
One more practical note that has nothing to do with either product: a hollow under the eye is often not the main problem. Skin quality, pigmentation and the position of the fat pads all contribute. A treatment aimed at one of those will not fix another.
Sudden change or loss of vision, blurred vision or double vision
Sudden severe pain, or pain out of proportion to the injection
Skin turning white or pale, then dusky, blotchy or mottled
Drooping on one side of the face, weakness in an arm or leg, or trouble speaking
These can mean an artery has been blocked. Time matters in hours, and this is true whether what was injected was filler or your own blood product.
Swelling under the eye or over the cheekbone keeps growing after a few days, or is still there weeks later
A lump or ridge appears that will not settle
The area looks blue-grey or shadowed in a way it did not before
Redness is spreading around the injection site, or you develop a fever
Tenderness, firmness or redness appears weeks after treatment
Filler appears to have moved out of the area it was placed in